Category Archives: Ohio Stem Cells

27 Nov 2019

Twenty years ago, researchers took fibroblasts from the skin of eight Alzheimers patients, engineered them to produce nerve-growth factor, and slid them into each volunteers basal forebrain. They hoped the neurotrophin would halt or slow the neurodegeneration that robbed them of their memories, indeed their lives. The gamble failed and since then, scientists have shown little zest for gene therapy in neurodegenerative disorders. That is changing. As evident at this years Society for Neuroscience conference, held October 1923 in Chicago, gene therapy is back. Buoyed by success in treating spinal muscular atrophy in infants, scientists are flush with new ideasand funding.

What was once considered risky, expensive, and unlikely to succeed is now seen by many as risky, expensiveand quite likely to succeed. A growing number of scientists think gene-based therapies may have the best chance of slowing, or even preventing, neurodegeneration, especially for disorders caused by mutations in a single gene. SfN hosted a press briefing on gene therapy, plus many projects are active throughout the field beyond those showcased at the conference. There was no breaking clinical trial news at the annual meeting, but the scope and challenges of such therapies were outlined at the briefing moderated by Rush University s Jeff Kordower, Chicago, as well as a translational roundtable moderated by Asa Abeliovich, Columbia University, New York. Abeliovich recently co-founded Prevail Therapeutics, New York.

Going viral. Researchers are tweaking the capsid of adeno-associated viruses to optimize gene therapies for a multitude of disease. Shown here, AAV2.

From Zolgensma to Alzheimers? If the failure of the nerve growth factor therapy tempered enthusiasm for gene therapy (Mar 2018 news), then the success of AVXS-101, aka Zolgensma, reignited it. Developed by scientists at Nationwide Childrens Hospital, Columbus, Ohio, and AveXis, Bannockburn, Illinois, AVXS-101 uses an adeno-associated virus to deliver billions of copies of the survival motor neuron 1 gene to the brain. A small pilot trial tested the therapy in babies with spinal muscular atrophy (SMA) Type 1, the severest form of this neurodevelopmental disease. Lacking functional SMN1, these infants face progressive muscle weakness. Most die before their second birthday; those who live need a ventilator to breathe.

In Phase 1, AVXS-101 dramatically improved motor function of 15 treated infants; all were living 20 months later when historical data predicted only one would survive. Twelve babies who received the highest dose grew stronger within months, most sitting independently and rolling over. They hit the highest score on a scale of motor function, whereas untreated babies deteriorated. By 20 months, two of the treated babies had begun to walk (Mendell et al., 2017). The Food and Drug Administration approved zolgensma in May 2019. At SfN in Chicago, Petra Kaufmann, AveXis, played videos of the first patients treated with AVXS-101. Some four years later, they are walking, running, and appear to be playing almost normally. A video of a little girl walking downstairs with nary a hint of having SMA Type I visibly moved the audience.

Scientists say its a game-changer. It is really the tremendous success with SMA that has renewed interest in gene therapy, said Clive Svendsen, Cedars-Sinai Regenerative Medicine Institute, Los Angeles. Speaking with Alzforum before SfN, Bart De Strooper, Dementia Research Institute, London, said the same. The success in SMA patients of both gene therapy and antisense therapy has revived interest in the whole area, De Strooper said. Nowadays, researchers tend to lump gene therapy and antisense therapy under one moniker, i.e., gene-based therapy. The SMA antisense therapy nusinersen also works in babies with SMA Type 1 and is FDA-approved (Nov 2016 news; May 2018 conference news). Unlike gene therapy, antisense therapy needs to be delivered indefinitely.

How About Neurodegenerative Disease?At SfN, scientists outlined strategies for treating adults who face years of decline due to Alzheimers, amyotrophic lateral sclerosis, frontotemporal dementia, Huntingtons (HD) and Parkinsons diseases (PD), or other synucleinopathies. Some are being tested in clinical trials, others are in preclinical development. Some target specific losses or gains of function, others aim to rescue dying neurons more broadly. Scientists also believe that working on rare childhood diseases of lysosomal storage may give them an opening to treat this common phenotype in age-related neurodegeneration, as well.

Just this October, an ApoE gene therapy trial started enrolling. Led by Ronald Crystal at Weill Cornell Medical College, New York, it will inject adeno-associated virus carrying the gene for ApoE2 into patients with early to late-stage AD who inherited two copies of ApoE4. The idea is to flood their brains with the protective allele of this apolipoprotein to try to counteract the effects of the risk allele. AAV-rh10-APOE2 will be injected directly into the subarachnoid cisternae of participants brains. The Phase 1 trialwill recruit 15 patients with biomarker-confirmed AD. Beverly Davidson, Childrens Hospital of Philadelphia, has a similar ApoE2 gene therapy in preclinical development.

At SfN, Abeliovich detailed Prevails programs for forms of PD and for frontotemporal dementias that are caused by risk alleles. A trial has begun for a glucocerebrosidase-based gene therapy. The enzyme GCase is essential for lysosomes to function properly. People who have loss-of-function mutations in both copies of the GBA1 gene develop Gauchers, a lysosomal storage disease. The severest form starts in babies, most of whom die before age 2. Milder forms cause later-onset Gauchers, while heterozygous mutations in GBA1 increase risk for Parkinsons, making restoration of GCase an obvious strategy for PD. Some researchers are trying to develop ways to boost activity of the mutated enzyme (e.g., Oct 2019 news), whereas Abeliovich and colleagues have constructed AAV-9 vectors to deliver normal GBA1 into the brain to restore GCase production.

In preclinical studies, the AAV9-GBA1 construct PR001 rescued both lysosomal and brain function in models of GCase deficiency and of Parkinsons, Abeliovich said. In mice fed the GCase inhibitor conduritol epoxide (CBE), PR001 injected into the brain ventricles beefed up GCase activity and reduced glycolipid accumulation, which is a sign that lysosomes are functional. A single dose worked for at least six months. Similar results were seen in a commonly used model of Gauchers that expresses the V394L GBA mutation and only weakly expresses prosaposin and saposins, lysosomal proteins that metabolize lipids. In these 4L/PS-NA mice, PR001 made increased levels of active GCase, fewer lipids accumulated, and the mice were more mobile on a balance beam. 4L/PS-NA mice also accumulate -synuclein, the major component of Lewy bodies in PD and other synucleinopathies. In these mice, and also in A53T -synuclein mice made worse with CBE, PR001 halved the amount of insoluble -synuclein, Abeliovich reported at SfN.

In search of the right dose for humans, the scientists next turned to nonhuman primates. They injected PR001 into the cisterna magna in hopes AAV9 would broadly distribute throughout the brain. At the highest dose, 8 x 1010 capsids per gram of brain weight, exposure in the brain was similar to that seen in the mice. The virus permeated the spinal cord, frontal cortex, hippocampus, midbrain, and putamen.

Also in October, Prevail scientists began recruiting for a Phase 1/2 double-blind, sham-controlled trial to test this gene therapy in 16 people with moderate to severe PD, who have mutations in one or both copies of their GBA1 genes. Six patients each will receive a low or high dose of PR001A. Blood and CSF biomarkers to be analyzed at three and 12 months, and at follow-up, include GCase, lipids, -synuclein, and neurofilament light chain. Participants will also undergo cognitive, executive, and motor-function tests and brain imaging. A Phase 1/2 trial of PR001 in neuronopathic Gauchers, which affects the brain and spinal cord, will start soon, Abeliovich said.

Other groups are boosting dopamine production in Parkinsons by way of gene therapy. VY-AADC,developed by Voyager Therapeutics, Cambridge, Massachusetts, packages the gene for L-amino acid decarboxylase (AADC), which converts L-dopa into dopamine, in an AAV-2 vector that is delivered into the brain. Two Phase 1 open-label trials are testing safety and efficacy. Both the PD-1101 and PD-1102 trials use MRI to guide injections of the vector bilaterally into the putamina of 15 or 16 patients, respectively. According to preliminary results presented at the annual meeting of the American Academy of Neurology this past May, the virus penetrated half of the putamen and AADC activity, as judged by 18F-DOPA PET, increased by 85 percent in the latter study. Seven of eight treated patients reported improvement after a year, along with longer on time on L-DOPA, and shorter off time. Off time is the period when L-DOPA effects wear off and patients experience loss of motor control. RESTORE-1, a Phase 2 study of 42 patients, started in 2018 and will run to the end of 2020.

Long-Lived Gene Therapy. When a Parkinsons disease patient died eight years after neurturin gene therapy, the trophin was still being expressed in their putamen (top left) and substantia nigra (bottom left), where it corresponded with tyrosine hydroxylase activity (right). [Courtesy of Jeff Kordower.]

Also in PD, Kordower and colleagues plan to re-evaluate neurturin-based gene therapy. Previously, the gene for this neurotrophin was delivered in an AAV2 vector into the brains of Parkinson patients in Phase 1 and 2 trials. This did not improve motor function. Even so, in Chicago Kordower showed that in two patients who died eight and 10 years later, the inserted gene was still expressing neurturin and that dopamine levels were higher on the injected than the contralateral side of the substantia nigra/putamen. This shows us that long-term gene expression can be achieved in the human brain, said Kordower (see image above). He believes that by focusing delivery with ultrasound, or tweaking the capsid itself, he may be able to generate enough gene expression to improve function.

Separately, AAV-GAD, a gene therapy for PD that showed promise in Phase 2 (Mar 2011 news) was acquired by MeiraGTx, New York, which will continue to develop it in the U.S. and Europe, according to founder Samuel Waksal (Nov 2018 news).

For its part, Prevail has a gene transfer construct for frontotemporal dementia in the pipeline, as well. Called PR006, it carries GRN, the gene encoding progranulin, on an AAV9 vector. GRN mutations cause familial FTD and, much like GBA mutations, do their dirty work via lysosomal dysfunction. In Chicago, Abeliovich reported that PR006 boosted progranulin release from neurons derived from FTD-GRN patients, nearly doubling their levels of mature Cathepsin D, the lysosomal protease that chops progranulin into granulins and indicates healthy lysosomes. In progranulin knockout mice, PR006 restored brain GRN expression and progranulin secretion into the CSF. Abeliovich said he expects a Phase 1/2 clinical trial in FTD patients to start in early 2020.

The biotech company Passage Bio, Philadelphia, is planning for clinical trials early next year with its AAV-GRN vector. MeiraGTx, New York, is banking on a different approach for FTD. They have developed an AAV carrying UPF1, which encodes regulator of nonsense transcripts 1. This protein helps clear out aberrant RNAs through a process call nonsense-mediated decay. MeiraGTx hopes this will restore homeostasis to RNA processing. AAV-UPF1 will be trialed for FTD and all forms of ALS bar those caused by mutations in SOD1. For SOD ALS, Novartis, Basel, Switzerland, and REGENXBIO, Rockville, Maryland, have a vector in preclinical testing.

For his part, Svendsen is taking a different approach. His lab tackles ALS with ex vivo gene therapy. The idea is to engineer clinical-grade human stem cells to produce glial-derived growth factor, and inject them into the spinal cord, much like the early NGF studies did in AD. Svendsen hopes the cells will churn out enough of the neurotrophin to protect spinal cord motor neurons. In a Phase 1/2a trial, 18 ALS patients have received these cells into one side of their spinal cords, such that each person serves as his or her own control. If this works, they would regain mobility only on the injected side. The trial finished in October; Svendsen expects results to come out in a few months. In a follow-up study, the scientists are trying to do the same with induced pluripotent stem cells. This would allow them to transplant autologous cells into patients, avoiding immune rejection

Other groups are deploying gene therapy as a way to improve immunotherapy, shield neurons from stress, or even generate neurons from astrocytes to make up for those lost to neurodegeneration.Tom Fagan

Read the rest here:
Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum

Huber R. Warner, Ph.D., a biochemist who led NIAs Biology of Aging Program, passed away suddenly on September 12 in St. Paul, Minn., at the age of 83.

Dr. Warner joined NIA in 1984 where he managed the Molecular Biology Program while also serving as chief, Biochemistry and Metabolism Branch. In January, 2000 he was named associate director of the NIA Biology of Aging Program. Warner played a large part in expanding the scope and scale of aging research at the NIA, while helping to mentor a new generation of scientists. His research interests included oxidative stress, molecular mechanisms of apoptosis, functional genomics and stem cells.

Huber was not only a well-respected scientist and leader in our field, but his gentle nature made him beloved by both the community and his colleagues, said Dr. Felipe Sierra, director of the NIA Division of Aging Biology (DAB).

Dr. Dick Sprott, Warners predecessor at the NIA DAB, said Dr. Warner served with diligence and great scientific acumen. While his insights were important for the biology of aging field, we will remember him for leadership and common sense. I, like many others, will always treasure his sound advice and friendship.

Dr. Richard Hodes, director of the NIA said The entire NIA family is saddened by the loss of Dr. Warner. He helped guide and grow the study of aging biology at the NIH and NIA with a steady hand and curious mind, and will be deeply missed.

Warner was born in 1936 in Glendale, Ohio. He received a doctorate in biochemistry from the University of Michigan in 1962, and following postdoctoral work at M.I.T., he joined the faculty of the Department of Biochemistry at the University of Minnesota, St. Paul, Minn., in 1964. He was a member of the American Society for Biochemistry and Molecular Biology and a Fellow of the Gerontological Society of America.

After leaving NIA in 2004, he returned to the University of Minnesota, where he served as associate dean of research until his retirement in 2010. He spent his later years at the Universitys independent living community, and returned often with family to his beloved Cawaja Beach in Ontario, Canada. Warner was known for his many athletic interests and as an enthusiastic volunteer coach for youth sports. He played hockey growing up, and tennis in his later years, and was a member of the NIH Tennis and Sailing clubs.

A memorial service celebrating Warner will be held on Saturday, November 16, at 1:00 p.m. at the University of Minnesota. He is survived by sons Geoffrey and Peter; daughter-in-law Dawn; and 3 granddaughters: Chloe, Laurel and Alexandra.

People interested in honoring Warner can make a tax-deductible donation to the "Huber Warner Fellowship in Molecular Biology, which supports a talented graduate student studying the mechanisms of aging. Donations can be made online or by sending a check to:

University of Minnesota Foundation200 Oak Street, SE, Suite 500Minneapolis, MN 55455-2010

More:
NIA Mourns the Loss of Dr. Huber Warner - National Institute on Aging

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Mutation Found in Dark Matter of the Genome New Target for Cancer

The so-called dark matter of the genome is the non-coding regions that make up about 98% of the genome. Researchers at the Ontario Institute for Cancer Research (OICR) recently identified a novel cancer-driven mutation in this region that is linked to brain, liver and blood cancer. They published the two studies in the journal Nature.

Non-coding DNA, which makes up 98% of the genome, is notoriously difficult to study and is often overlooked since it does not code for proteins, said Lincoln Stein, co-lead of the two research studies and Head of Adaptive Oncology at OICR. By carefully analyzing these regions, we have discovered a change in one letter of the DNA code that can drive multiple types of cancer. In turn, weve found a new cancer mechanism that we can target to tackle the disease.

The mutation is dubbed U1-snRNA, and it appears to disrupt normal RNA splicing, which changes the transcription of genes that drive cancer. The mutation was identified in tumors of patients with specific subtypes of brain cancer and was found in almost all of the samples. The cancer was sonic hedgehog medulloblastoma. It was also found in samples of chronic lymphocytic leukemia (CLL) and hepatocellular carcinoma.

Our unexpected discovery uncovered an entirely new way to target these cancers that are tremendously difficult to treat and have high mortality rates, said Michael Taylor, pediatric neurosurgeon and senior scientist in Development and Stem Cell Biology and Garron Family Chair in in Childhood Cancer Research at The Hospital for Sick Children and co-lead of the studies. Weve found that with one typo in the DNA code, the resultant cancers have hundreds of mutant proteins that we might be able to target using currently available immunotherapies.

Diagnosing Lyme Disease in 15 Minutes

About 300,000 people are diagnosed with Lyme disease each year. Borrelia burgdorferi is transmitted by the bite of infected Ixodes ticks, and if untreated, can cause neurologic, cardiac, and rheumatologic complications. Current testing involves two complex tests, ELISA and western blot. Researchers have developed a rapid microfluidic test that can provide comparable results in as little as 15 minutes. It will require more refinement and testing before widespread use.

Gene Therapy for Wet Age-Related Macular Degeneration Shows Promise

Research was recently presented on six patients who received a gene therapy for wet age-related macular degeneration (AMD). The patients have gone at least six months without continued injections for the disease that were previously required every four to six weeks. The therapy, which is injected into the eye, generates a molecule much like aflibercept, a broadly used anti-VEGF drug.

How Dementia Spreads Throughout Brain Networks

Frontotemporal dementia (FDT) is similar to Alzheimers disease, but tends to hit patients earlier and affects different parts of the brain. Researchers studied how well neural network maps made from brain scans in healthy people could predict the spread of brain atrophy in FTD patients over several years. They recruited 42 patients at the UCSF Memory and Aging Center with a form of FTD and 30 with another form. They received MRI scans and then follow-up scans a year later to determine how the disease had progressed. They found that the standardized connectivity maps were able to predict the spread of the disease.

Mucus and Microbes: A Therapeutic Gold Mine.

A specific type of molecule called glycans that are found in mucus prevent bacteria from communicating with each other. Mucus also prevents the bacteria from forming infectious biofilms. It is also pointed out that more than 200 square meters of our bodies are lined with mucus. There are hundreds of different types of glycans found in mucus, and most of them are responsible for suppressing bacteria. Katharina Ribbeck, a professor at the Massachusetts Institute of Technology, says, What we have in mucus is a therapeutic gold mine.

Mechanisms that Regulate Brain Inflammation

The role of brain inflammation in diseases like Alzheimers and Parkinsons is becoming better understood. Researchers recently identified mechanisms that regulate brain inflammation, which has the potential to open new avenues for treating and preventing these diseases. The scientists found that a protein called TET2 modulates the immune response in microglia, immune cells in the brain, during inflammation. In mice engineered not to have TET2 in the microglia, neuroinflammation is reduced. Normally, TET2 with other proteins regulates the activity of genes by removing specific chemical markers from DNA, but TET2 appears to behave differently in microglia.

Pilot Study: Even Short-Term Vaping Causes Lung Inflammation

Research out of The Ohio State University Comprehensive Cancer Center found cellular inflammation was caused by e-cigarette, i.e., vaping, use in both long-term smokers and people who did not smoke. They used bronchoscopy to evaluate for inflammation and smoking-related effects and found a measurable increase in inflammation after only four weeks of vaping without nicotine or flavors. The amount of inflammation was small compared to the control group, but the data suggests that even short-term use can result in inflammatory changes at a cellular level. Inflammation in smoking is a driver of lung cancer and other respiratory diseases.

View post:
Research Roundup: Genomic Dark Matter Mutation and More - BioSpace

Stem Cell Treatment

Arthritic conditions and some types of injuries affecting the joints and extremities have been historically challenging to treat. Until recently, treatment focus was on managing symptoms, rather than getting to the core of the problem. Today, there is a revolutionary treatment available at the Orthopaedic Institute of Ohio that restores healing to injured areas and reverses the painful effects of arthritis. Stem cell injections are now offered to stimulate the patients own body to repair damage and restore function after injury or disease.

Stem cells are undifferentiated cells in the body that have the unique ability to transform into any cell or tissue. This exceptional property allows for reparative function when the stem cells are delivered into injured or diseased areas of the body in need of regeneration. This concentration of regenerative cells combines with cells already working to restore the area, boosting the power of the body to heal itself quickly and thoroughly. At the same time stem cells repair damaged cartilage and bone, they also reduce uncomfortable side effects like swelling, inflammation and pain.

Concentrated bone marrow aspirate or cBMA is a therapy that uses stem cells taken from the pelvis bone and delivers them to the injured area to stimulate the bodys natural healing responses. The bone marrow is removed through an outpatient procedure using a local anesthetic. The extracted bone marrow is then placed into a centrifuge to separate the stem cells from the rest of the marrow material. Next, the stem cells are injected into the treatment area, where they will likely reduce symptoms and improve the function of the joint or limb within a matter of weeks.

Our cBMA therapy can be used to address a variety of areas and concerns, including:

Our surgeons at Orthopaedic Institute of Ohio will evaluate your injury to determine whether stem cell injections might bring the desired relief. Since we offer a wide range of treatment options, we can tailor your procedure to your unique situation to produce the best possible outcome for you.

Stem cell injections typically take about two hours to perform in our office. We will provide a local anesthetic to the donor area to ensure your comfort during the procedure. The bone marrow will be removed using a suction syringe placed at the back of the hip. The collected marrow will be processed in a centrifuge, and the remaining stem cells and healing components are then delivered directly to the treatment area. Some areas may need ultrasound or X-Ray guidance.

Patients are usually sore for a few days after the stem cell injections, particularly at the donor site. Most feel ready to return to regular activities within about one week. Physical therapy may be prescribed to optimize the effects of stem cell therapy. Patients often begin to see positive results within two to six weeks after their procedure.

If you are suffering chronic pain and reduced mobility due to an injury that wont heal completely or an arthritic condition, stem cell injections may be an option for you. Contact the Orthopaedic Institute of Ohio today at 419-222-6622 to schedule a consultation and learn more about this revolutionary treatment.

See the rest here:
Stem Cell Treatment Lima | Orthopaedic Institute of Ohio

The video above is Dr. Nick Fabian from our Elyria location talking about Regenerative Therapyduring a Facebook live segment with Jenny from the Block on Fox 8 Cleveland.

Unlike other cells, stem cells are unspecialized or undifferentiated in our bodies that have the capacity to change into any healthy cell in our body. Meaning they can change into skin, bone, heart, and muscle cells to name a few. They have the unique ability to divide or differentiate into many types of cells with specific functions such as muscle, skin or bone cells.

Stem cells can also give rise to new generations of undifferentiated stem cells, thus renewing themselves. Stem cells are located throughout our body in almost every organ and tissue such as bone marrow, fat, teeth, muscles, etc.

While cortisone and other drugs only provide temporary pain relief, Regenerative Therapy actually restores degenerated tissue while providing pain relief. Additionally, the injections contain collagen, proteins and hyaluronic acid, which acts as a lubricant on worn and damaged joints while encouraging new, healthy cartilage tissue growth.

Some people will feel immediate relief from their pain and will notice continued improvements in pain reduction, mobility, and range of motion following the treatment. Most results are seen within one to three months after injection.

The wonderful thing about Regenerative Therapy is that its being found to be a safer and more effective pain relief treatment than addicting prescription medications and surgeries that require weeks and sometimes months downtime from your active life.

However, this therapy doesnt just put a Band-Aid on the problem and walk away; it encourages your own body to start healing. The end result is reduced or eliminatedpain, healthier joint tissue, increased mobility, and the ability to once again engage in all of your favorite activities, allowing you to live a vibrant, healthy, and pain-free life!

View original post here:
Regenerative Therapy in Northeast Ohio | Ohio Therapy Centers

Dr. Joe Ruane, Medical Director of McConnell Spine, Sport & Joint Physicians is pleased to bring mesnechymal stem cell therapy, also known as cellular medicine or orthobiologic therapy, to the McConnell Spine, Sport & Joint Center.

McConnell Spine, Sport & Joint Physicians were among the first in the area to offer platelet-rich plasma (PRP) therapy, and will be offering stem-cell treatments as the next optioin in the rapidly expanding field of regenerative orthopedic medicine. This treatment option is for active adults who are no longer find relief from traditional treatments, or may be hoping to avoid surgery.

Orthobiologic treatment takes healthy cells from your own body with a high potential to regenerate tissue, and injects the cells into the injured area of your body, enabling your body to better heal itself. Mesenchymal stem cells are the specific cells used in orthopedic treatments. Theses cells have the potential to help your bodys ability to naturally repair muscle, bone, joint and soft tissue.

I have been watching the field of orthobiologics grow and mature for several years, and it is now being offered by reputable providers across the country, Dr. Ruane said. It is considered the future of musculoskeletal medicine and we need to push forward into this exciting area.

Dr. Ruanes training and certification:

To learn more or to schedule an appointment, call (614) 566-3810

Originally posted here:
Stem cell therapy now available in central Ohio!

If youre in need of relief from from chronic pain or help healing an injury, Regen Orthopedics may have a solution for you.

Through advanced regenerative medicine treatments, your bodys own platelets, stem cells and growth factors can be activated to stimulate healing and speed repair for bone, muscle, joint, soft tissue, and nerve injuries. These pain therapies can enable your body to repair injured tissues, reduce inflammation and ultimately heal itself.This regenerative, non-surgical treatment has been very effectivefor many patients who havent experienced adequate relief with conventional treatments such as anti-inflammatory medications, cortisone injections, physical therapy or surgery.

At Regen Orthopedics, we follow FDA guidelines for regenerative procedures using your own, live adult stem cells. Using your own stem cells is safer and more effective. Studies have shown that stem cell products made from amniotic or cord blood tissues do not contain any actual live stem cells by the time they are injected into a patient. Learn more here.

We utilize bone marrow concentrate (BMC), known as the gold standard among leaders in the field of regenerative medicine. This involves a relatively painless procedure performed by a highly skilled orthopedic specialist using ultrasound guidance to ensure proper placement.

When you make the decision to have a regenerative procedure, you want to ensure you are in the hands of a highly qualified medical professional. We are experts in orthopedic conditions, and our patients are cared for by nationally renowned orthopedic surgeon, Reuben Gobezie, MD. Regen Orthopedics also employs a research team that follows our patients to measure their success. Be extremely cautious when considering having this procedure done by anyone other than a skilled physician who is highly trained in orthopedics. Please read more on the questions you should ask if you consider donated stem cells products here.

Many of our patients have been able to avoid surgery and ongoing pain medications. For patients trying to regain mobility, return to activity or sport, and arthritis patients in particular, regenerative medicine is changing the game in orthopedic care.

Regen Orthopedics is a member of the Orthobiologic Ethics Consortium. This multi-disciplinary group of like-minded health care providers supports the ethical research, marketing and clinical use of orthobiologics and regenerative medicine. Orthobiologic modalities are defined as living cells or other substances or materials that can affect the healing of bone, cartilage, tendon, ligament, muscle or nerve.

As an early adopter of using regenerative treatments in orthopedics, Regen Orthopedics serves as an advocate for patient safety, highest quality and the use of best practices in all regenerative procedures.

Excerpt from:
Stem Cell Therapy Clinic in Cleveland, Ohio

Customized Spa Facial Includes skin analysis, cleansing, exfoliating, treatment mask and a relaxing hand & arm and foot & leg massage to rejuvenate and protect your skin.$89

Mini Facial Includes a deep cleansing with a skin analysis, treatment masque, and moisturizer.$59

Gentlemans Facial Includes a skin analysis, cleansing, treatment mask, and relaxing hand & arm massage to rejuvenate and protect your skin. (Please arrive clean shaven)$79

Seasonal Spa Facial This classic facial includes cleansing, exfoliating, treatment masque, moisturizer, and a relaxing hand & arm massage, featuring seasonally scented Farmhouse Fresh products.$79

Anti-aging FacialThe maximum in anti-aging prevention and hydration. The treatment starts with cleansing and moves to exfoliating treatments, containing plant-derived stem cells, peptides, AHAs and Vitamin C, to provide the maximum in correction, prevention, and nutrition. $99

Signature Lift -Vitamin C and fruit enzymes blended in an organic aloe vera base visibly reduce redness and brighten the skin while hyaluronic acid provides superior hydration. Skin type indications: Redness-prone, dry/dehydrated, smokers skin, tired/ dull, post-microdermabrasion, oily/acne. $89

O2 Lift -This luxurious skin care treatment infuses oxygen, plant-derived stem cells, peptides and a high concentration of enzymatic botanicals into the skin leaving it luminous, refreshed and rejuvenated. $79

Dermaplaining -Amethod of manual exfoliation and removes the outer most layers of dead skin cells and hair leaving the skin immediately smooth, supple and vibrant. $89

Read this article:
Massages & Treatments | Day Spa on Lake Erie in Ohio | The ...

The video above is Dr. Nick Fabian from our Elyria location talking about Regenerative Therapyduring a Facebook live segment with Jenny from the Block on Fox 8 Cleveland.

Unlike other cells, stem cells are unspecialized or undifferentiated in our bodies that have the capacity to change into any healthy cell in our body. Meaning they can change into skin, bone, heart, and muscle cells to name a few. They have the unique ability to divide or differentiate into many types of cells with specific functions such as muscle, skin or bone cells.

Stem cells can also give rise to new generations of undifferentiated stem cells, thus renewing themselves. Stem cells are located throughout our body in almost every organ and tissue such as bone marrow, fat, teeth, muscles, etc.

While cortisone and other drugs only provide temporary pain relief, Regenerative Therapy actually restores degenerated tissue while providing pain relief. Additionally, the injections contain collagen, proteins and hyaluronic acid, which acts as a lubricant on worn and damaged joints while encouraging new, healthy cartilage tissue growth.

Some people will feel immediate relief from their pain and will notice continued improvements in pain reduction, mobility, and range of motion following the treatment. Most results are seen within one to three months after injection.

The wonderful thing about Regenerative Therapy is that its being found to be a safer and more effective pain relief treatment than addicting prescription medications and surgeries that require weeks and sometimes months downtime from your active life.

However, this therapy doesnt just put a Band-Aid on the problem and walk away; it encourages your own body to start healing. The end result is reduced or eliminatedpain, healthier joint tissue, increased mobility, and the ability to once again engage in all of your favorite activities, allowing you to live a vibrant, healthy, and pain-free life!

This slideshow requires JavaScript.

Original post:
*NEW* Regenerative Stem Cell Therapy | Ohio Therapy Centers

Amniotic regenerative cell therapy is one of the newest and most cutting-edge therapies for chronic joint pain. Amniotic derived regenerative cell therapy offers patients 3 essential properties for healing and restoring joint health:

Since amniotic derived regenerative cell therapy is not derived from embryonic stem cells or fetal tissue, there are no ethical issues with the treatment. The amniotic regenerative cell therapy consists of an injection directly into the painful area. The therapy has the potential to actually alter the course of the condition and not simply mask the pain. This therapy has significant potential for those in pain, and could actually repair structural problems while treating pain and inflammation simultaneously. When the amniotic cell material is obtained, it comes from consenting donors who have undergone elective c-sections. The fluid is processed at an FDA regulated lab, and is checked for a full slate of diseases per FDA guidelines. The amniotic material has been used over 60,000 times in the US with no adverse events reported. It acts as an immunologically privileged material, meaning it has NOT been shown to cause any rejection reaction in the body. This means there is no graft versus host problem.

Our services are provided by Dr. John Biery D.O. F.A.O.S.M. F.A.C.S.M. F.A.C.O.F.P

Lauren Sherer P.A.

Read more here:
Stem Cell Therapy | Ohio Stem Cell